On the other hand, SMM patients could be the best subset of patients for the use of immunecheckpoint inhibitors as further supported by the results from Dhodapkar et al., on the correlation between PD-L1 expression and the risk of disease progression which suggest that PD-L1 blockade in early stages of disease could prevent MM progression (28). This evidence concerns the gene CD274 and Miyoshi myopathy.